Momentum Burst Setup?Is this a good example of a momentum burst set up?
The price has made a 4% move today where I have made the buy.
The preceding 3 days have been small range days and in all 3 sessions the market closed below the open i.e. down days.
There has been an orderly consolidation with price moving sidewa
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.65 EUR
−122.97 M EUR
809.10 M EUR
88.35 M
About Myriad Genetics, Inc.
Sector
Industry
CEO
Samraat S Raha
Website
Headquarters
Salt Lake City
Founded
1991
ISIN
US62855J1043
FIGI
BBG000KNHDH1
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Related stocks
MYGN second cupFound a cup on this volatile stock. Previous cup made it to the 62% mark which is impressive.
Very weird handle. Seems to be in a broadening pattern and then is in an ascending triangle pattern. I would say wait to break cup top which should be soon.
T1: 38% depth at $39.50 and 62% depth at $44.
MYRIAD GENETICS Chart Hello traders, MYRIAD GENETICS is in a fake bearish configuration with a large buying volume executed and a water carrying candle accompanied by a very strong lower leg. Looking at the TIMEFRAME M1 we see a marubozu with a large negotiated purchase volume, it goes towards the base of the bollinger f
MYGN TankI thought about it and didn't publish this because my earnings plays for today didn't play out like it should have. CENT and USX both lost money but apparently "beat estimates", which is hilarious when the estimate is a loss. You'd think they were tech companies or something. At least CENT went d
Risk Reward, Plenty of Potential vs ProblemsMYGN has been a player for a while, large company, with actual earnings, however litigation and companies are generally a bad thing. "healthy" enough of a chart for me to participate, but I will not have much patience to the downside, stop in place.
**Long this last collapse, limited in size... co
Looking for a Nice Rebound to 31I think this stock will recover some of it's losses, regardless of the outcome of the potential FDA restrictions on drug suggestions. The stock has a solid business model and the company has said they are seeing increased demand. This new fields of genetics testing still needs to establish itself in
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Myriad Genetics, Inc. stocks are traded under the ticker MYD.
We've gathered analysts' opinions on Myriad Genetics, Inc. future price: according to them, MYD price has a max estimate of 15.43 EUR and a min estimate of 3.00 EUR. Watch MYD chart and read a more detailed Myriad Genetics, Inc. stock forecast: see what analysts think of Myriad Genetics, Inc. and suggest that you do with its stocks.
Yes, you can track Myriad Genetics, Inc. financials in yearly and quarterly reports right on TradingView.
Myriad Genetics, Inc. is going to release the next earnings report on Nov 4, 2025. Keep track of upcoming events with our Earnings Calendar.
MYD earnings for the last quarter are 0.04 EUR per share, whereas the estimation was −0.01 EUR resulting in a 742.59% surprise. The estimated earnings for the next quarter are −0.01 EUR per share. See more details about Myriad Genetics, Inc. earnings.
Myriad Genetics, Inc. revenue for the last quarter amounts to 180.90 M EUR, despite the estimated figure of 171.36 M EUR. In the next quarter, revenue is expected to reach 174.97 M EUR.
MYD net income for the last quarter is −280.56 M EUR, while the quarter before that showed −92.43 K EUR of net income which accounts for −303.43 K% change. Track more Myriad Genetics, Inc. financial stats to get the full picture.
No, MYD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 2, 2025, the company has 2.7 K employees. See our rating of the largest employees — is Myriad Genetics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Myriad Genetics, Inc. EBITDA is −15.20 M EUR, and current EBITDA margin is −3.10%. See more stats in Myriad Genetics, Inc. financial statements.
Like other stocks, MYD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Myriad Genetics, Inc. stock right from TradingView charts — choose your broker and connect to your account.